NCT04161391: Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: RET
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have solid tumor(s) harboring RET fusions or mutations
Exclusions: Patients with symptomatic brain metastases that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT04161391

Comments are closed.

Up ↑